Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 2
1983 1
1984 3
1985 2
1986 1
1987 1
1988 1
1989 1
1998 1
2000 1
2001 3
2002 2
2003 6
2004 4
2005 10
2006 3
2007 2
2011 3
2012 4
2013 1
2015 3
2016 2
2018 1
2019 2
2020 1
2021 1
2022 1
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators. James ND, et al. Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21. Lancet. 2016. PMID: 26719232 Free PMC article. Clinical Trial.
Anti-spasticity agents for multiple sclerosis.
Shakespeare DT, Boggild M, Young C. Shakespeare DT, et al. Cochrane Database Syst Rev. 2003;(4):CD001332. doi: 10.1002/14651858.CD001332. Cochrane Database Syst Rev. 2003. PMID: 14583932 Review.
Anti-spasticity agents for multiple sclerosis.
Shakespeare DT, Boggild M, Young C. Shakespeare DT, et al. Cochrane Database Syst Rev. 2001;(4):CD001332. doi: 10.1002/14651858.CD001332. Cochrane Database Syst Rev. 2001. PMID: 11687107 Updated. Review.
Anti-spasticity agents for multiple sclerosis.
Shakespeare DT, Young CA, Boggild M. Shakespeare DT, et al. Cochrane Database Syst Rev. 2000;2003(4):CD001332. doi: 10.1002/14651858.CD001332. Cochrane Database Syst Rev. 2000. PMID: 11034714 Free PMC article. Updated. Review.
Stroke mortality datasets.
Barrett JA, Owens VB, Little V, Weir P, Plant R, Shakespeare DT, Sangster G, Maxwell M. Barrett JA, et al. Among authors: shakespeare dt. Age Ageing. 2004 Sep;33(5):502-4. doi: 10.1093/ageing/afh139. Age Ageing. 2004. PMID: 15315920 No abstract available.
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, Petersen PM, Persad RA, Saad F, Bower LC, Logue J, Payne H, Forcat S, Goldstein C, Murphy C, Anderson J, Barkati M, Bottomley DM, Branagan J, Choudhury A, Chung PWM, Cogley L, Goh CL, Hoskin P, Khoo V, Malone SC, Masters L, Morris SL, Nabid A, Ong AD, Raman R, Tarver KL, Tree AC, Worlding J, Wylie JP, Zarkar AM, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 May 16:S0140-6736(24)00548-8. doi: 10.1016/S0140-6736(24)00548-8. Online ahead of print. Lancet. 2024. PMID: 38763154 Free article.
Campaign best practice in intravenous therapy.
Baldwin W, Murphy J, Shakespeare D, Kelly C, Fox L, Kelly M. Baldwin W, et al. Among authors: shakespeare d. Nurs Times. 2013 Aug 21-Sep 3;109(33-34):22-3. Nurs Times. 2013. PMID: 24079094
63 results